Understanding Reglan and Tardive Dyskinesia

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Specific Legal Concerns

If you or a loved one has taken Reglan and noticed uncontrollable facial or body movements, you may be wondering about tardive dyskinesia. This serious movement disorder is a known risk of long-term metoclopramide use. Over the years, medical research has built a solid understanding of how this medication affects the nervous system. Here we answer common questions about Reglan and tardive dyskinesia, from early symptoms to monitoring and management.

Understanding Reglan and Its Approved Uses

Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux that has not responded to conventional therapy, and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA-approved labeling includes a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the medication should be used for the shortest duration necessary, with periodic reassessment of the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If signs or symptoms of TD develop, Reglan should be discontinued immediately (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Tardive Dyskinesia: Symptoms, Mechanism, and Risk Factors

Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, and/or extremities, which can be disfiguring and may not resolve even after the medication is stopped (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The condition can be masked or suppressed by continued use of metoclopramide, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, total treatment duration should also be avoided beyond 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan tablets are not recommended for use in pediatric patients due to the risk of developing TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to tardive dyskinesia involves dopamine receptor blockade in the basal ganglia, which can lead to supersensitivity of dopamine receptors over time. This pharmacological effect is consistent with the known adverse effects of metoclopramide, a dopamine antagonist. The clinical presentation of TD includes orofacial movements such as lip smacking, chewing, and tongue protrusion, as well as choreiform movements of the limbs and trunk. Diagnosis is based on clinical examination and history of exposure to a dopamine-blocking agent like Reglan. The timeline between exposure and documented harm can vary; TD may develop after weeks, months, or years of treatment, but the risk increases with longer duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Some cases may emerge after discontinuation of the drug, as the masking effect of metoclopramide wears off.

Legal Considerations for Washington Residents

From a risk perspective, the adequacy of warnings regarding Reglan and TD is a critical consideration. The boxed warning clearly states the risk, but patients may not have been adequately informed about the potential for irreversible movement disorders, especially when the medication is used beyond the recommended 12-week limit. Attorney-related considerations for affected patients in Washington include the statute of limitations for filing a claim. In Washington, the statute of limitations for personal injury claims, including those related to medication-induced harm, is generally three years from the date the injury was discovered or reasonably should have been discovered. For TD, this may be when symptoms first appear or when a diagnosis is made. Given that TD can develop insidiously and may be masked by continued Reglan use, the timeline for discovery can be complex. Patients who have developed TD after using Reglan should consult with an attorney experienced in pharmaceutical litigation to evaluate their case, as the statute of limitations may vary based on individual circumstances and the date of last exposure. In summary, Reglan is associated with a known risk of tardive dyskinesia, a potentially irreversible movement disorder, with risk increasing with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The medication is indicated only for short-term use in adults, and patients should be monitored for TD symptoms. For those affected in Washington, legal action must be pursued within the applicable statute of limitations, which typically begins when the injury is discovered. Given the serious nature of TD and the clear warnings in the prescribing information, patients who have experienced harm may have grounds for a claim if the medication was used beyond recommended durations or without adequate monitoring.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan tardive dyskinesia claims in Washington?

In Washington, the statute of limitations for personal injury claims, including those related to medication-induced harm, is generally three years from the date the injury was discovered or reasonably should have been discovered. For tardive dyskinesia, this may be when symptoms first appear or when a diagnosis is made. Given the insidious onset and potential masking by continued Reglan use, the discovery date can be complex. It is crucial to consult with an attorney experienced in pharmaceutical litigation to evaluate your specific case.

What are the symptoms of tardive dyskinesia caused by Reglan?

Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, and/or extremities. Common symptoms include lip smacking, chewing, tongue protrusion, and choreiform movements of the limbs. These movements can be disfiguring and may not resolve even after stopping Reglan. The condition can be masked by continued use of the medication, potentially delaying diagnosis.

How long can Reglan be used safely?

Reglan is approved for short-term use only. For symptomatic gastroesophageal reflux, the maximum duration is 12 weeks. For diabetic gastroparesis, treatment should also be limited to 12 weeks. Longer-term use increases the risk of developing tardive dyskinesia, and routine monitoring is recommended if extended use is unavoidable. The FDA boxed warning emphasizes using the lowest effective dose for the shortest duration necessary.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.